Merus (NASDAQ:MRUS) Lowered to Sell at StockNews.com (2024)

Merus (NASDAQ:MRUS – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

Other analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of Merus in a report on Thursday, May 9th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of Merus in a report on Monday, May 13th. BMO Capital Markets raised their price target on shares of Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Stifel Nicolaus raised their price target on shares of Merus from $40.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Finally, Truist Financial began coverage on shares of Merus in a report on Thursday, March 28th. They issued a “buy” rating and a $69.00 price target for the company. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Merus has a consensus rating of “Moderate Buy” and an average price target of $56.33.

Check Out Our Latest Report on Merus

Merus Stock Performance

NASDAQ MRUS opened at $43.72 on Wednesday. The firm has a 50-day simple moving average of $44.35 and a 200 day simple moving average of $36.94. Merus has a twelve month low of $19.81 and a twelve month high of $52.03. The stock has a market cap of $2.57 billion, a PE ratio of -15.78 and a beta of 1.10.

Merus (NASDAQ:MRUS – Get Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. The firm had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. Research analysts forecast that Merus will post -3.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Merus

Several large investors have recently modified their holdings of MRUS. Virtu Financial LLC bought a new position in shares of Merus in the first quarter valued at $555,000. Artal Group S.A. bought a new position in shares of Merus during the first quarter valued at about $20,492,000. California State Teachers Retirement System boosted its stake in Merus by 2.9% in the first quarter. California State Teachers Retirement System now owns 33,745 shares of the biotechnology company’s stock valued at $1,520,000 after acquiring an additional 936 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Merus by 2.2% in the first quarter. Janus Henderson Group PLC now owns 542,580 shares of the biotechnology company’s stock valued at $24,427,000 after acquiring an additional 11,536 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Merus in the first quarter valued at approximately $53,377,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Company Profile

(Get Free Report)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Read More

• Five stocks we like better than Merus
• What Are Growth Stocks and Investing in Them
• AutoZone Pulling Back Into the Buy Zone
• Are Penny Stocks a Good Fit for Your Portfolio?
• How to Invest in NASDAQ: An Easy-to-Follow Guide
• How to Calculate Return on Investment (ROI)
• Buy the Dip in Palo Alto Networks; Analysts Raise Targets

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.